期刊
DRUG DISCOVERY TODAY
卷 28, 期 10, 页码 -出版社
ELSEVIER SCI LTD
DOI: 10.1016/j.drudis.2023.103738
关键词
serum albumin; half-life extension; drug delivery; albumin-binding domain; long-acting therapeutics
This review evaluates the current state of knowledge regarding various aspects of ABMs and the unique advantages of ABM-mediated drug delivery. It also discusses how ABMs can be specifically modulated to maximize potential benefits in clinical development.
Human serum albumin (HSA) is the most abundant protein in the blood and has desirable properties as a drug carrier. One of the most promising ways to exploit HSA as a carrier is to append an albumin-binding moiety (ABM) to a drug for in situ HSA binding upon administration. Nature-and library-derived ABMs vary in size, affinity, and epitope, differentially improving the pharmacokinetics of an appended drug. In this review, we evaluate the current state of knowledge regarding various aspects of ABMs and the unique advantages of ABM-mediated drug delivery. Furthermore, we discuss how ABMs can be specifically modulated to maximize potential benefits in clinical development.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据